Oxaliplatin
- Generic Name
- Oxaliplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O4Pt
- CAS Number
- 61825-94-3
- Unique Ingredient Identifier
- 04ZR38536J
- Background
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...
- Indication
Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
- Associated Conditions
- Advanced Colorectal Cancer, Stage III Colon Cancer
- Associated Therapies
- -
Preoperative Pembrolizumab Plus Bevacizumab Combined With Chemotherapy in Patients With pMMR/MSS Locally Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT05585814
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
- Conditions
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 1040
- Registration Number
- NCT05568095
- Locations
- 🇺🇸
UCLA Ronald Reagan Med Ctr, Santa Monica, California, United States
🇺🇸Smillow Cancer Hosp, New Haven, Connecticut, United States
🇺🇸Regions Hospital, Saint Louis Park, Minnesota, United States
A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 50
- Registration Number
- NCT05567835
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸Baylor College of Medicine Medical Center - McNair Campus, Houston, Texas, United States
🇺🇸Baylor St. Luke's Medical Center, Houston, Texas, United States
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
- Conditions
- Advanced Biliary Tract CarcinomaAdvanced Gallbladder CarcinomaAdvanced Intrahepatic CholangiocarcinomaRecurrent Biliary Tract CarcinomaRecurrent Gallbladder CarcinomaRecurrent Intrahepatic CholangiocarcinomaStage III Distal Bile Duct Cancer AJCC v8Stage III Gallbladder Cancer AJCC v8Stage III Hilar Cholangiocarcinoma AJCC v8Stage III Intrahepatic Cholangiocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT05564403
- Locations
- 🇺🇸
Northwestern Medicine Grayslake Outpatient Center, Grayslake, Illinois, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Conditions
- Metastatic HER2-Negative Breast CarcinomaLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Malignant Female Reproductive System NeoplasmRecurrent Ovarian CarcinomaUnresectable HER2-Negative Breast CarcinomaUnresectable Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
- Interventions
- Procedure: BiopsyDrug: AlpelisibDrug: BinimetinibProcedure: Bone Marrow AspirationProcedure: Biospecimen CollectionProcedure: Bone ScanDrug: IpatasertibProcedure: Computed TomographyProcedure: EchocardiographyDrug: Nilotinib Hydrochloride MonohydrateBiological: PanitumumabProcedure: Magnetic Resonance ImagingDrug: PaclitaxelDrug: SotorasibDrug: OlaparibDrug: FluorouracilProcedure: Mutation Carrier ScreeningDrug: Neratinib MaleateDrug: LeucovorinDrug: FulvestrantProcedure: Positron Emission TomographyDrug: PalbociclibProcedure: Multigated Acquisition ScanDrug: Selumetinib SulfateDrug: Oxaliplatin
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2900
- Registration Number
- NCT05564377
- Locations
- 🇺🇸
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea, Michigan, United States
🇺🇸Corewell Health Dearborn Hospital, Dearborn, Michigan, United States
🇺🇸Corewell Health Farmington Hills Hospital, Farmington Hills, Michigan, United States
The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer (TORCH-E）
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 34
- Registration Number
- NCT05555888
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- University Hospital, Grenoble
- Target Recruit Count
- 52
- Registration Number
- NCT05546853
- Locations
- 🇫🇷
CHU de GRENOBLE ALPES, Grenoble, Alpes, France
🇫🇷CHU de BORDEAUX, Bordeaux, France
🇫🇷CHRU Lille, Lille, France
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Kimberly Perez, MD
- Target Recruit Count
- 8
- Registration Number
- NCT05546411
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2023-03-09
- Target Recruit Count
- 38
- Registration Number
- NCT05536102
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, China
Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes
- Conditions
- Interventions
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Fujian Medical University
- Target Recruit Count
- 203
- Registration Number
- NCT05524974
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.